

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wadih Arap, et al. Serial No.: 10/530,168

Filed: February 23, 2006

For: COMPOSITIONS AND METHODS OF USE OF TARGETING PEPTIDES FOR DIAGNOSIS AND THERAPY OF

HUMAN CANCER

Confirmation No. 5612

Group Art Unit: 1643

Examiner: Natarajan, Meera

Attv. Dkt. No.: UTSC:857US

STATEMENT OF THE SUBSTANCE OF THE INTERVIEW

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Commissioner:

This paper is submitted in response to the Interview Summary mailed on December 23, 2008, in which a Statement of the Substance of the Interview is required.

It is believed that no fees are due in connection with this filing; however if any additional fees are required, please consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSC:857US.

Remarks begin on page 2.

REMARKS

Applicants are in receipt of the Examiner's interview summary mailed December 23, 2008 regarding a telephonic interview held with the Examiner on December 17, 2008, and provides the following statement of interview.

The telephonic interview was held on December 17, 2008, and the rejections of claims 1 and 14 were discussed. Applicants' representative pointed out that the Arap et al. document cited as prior art was not prior art and was similar in disclosure to Applicants' own priority document. Applicants' representative then pointed out that claim 14, and claims depending therefrom, should be considered free of the prior art. The Examiner generally agreed based on the record before her. However, the Examiner pointed out that claim 1, directed to a broader targeting sequence, would still be subject to rejection.

Respectfully submitted,

David L. Parker Reg. No. 32,165

Reg. No. 32,165 Attorney for Applicants

Date:

January 8, 2009